Antengene Pharma repurchases shares at an unspecified cost
Antengene Pharma reported repurchasing shares; the number of shares and cost are not included here.
Related stories
JPMorgan Downgrades Coursera to Neutral, Sets $5 Price Target
JPMorgan downgraded Coursera to Neutral from Overweight and set a $5 price target.
M impact | EQUITY | Oct 30, 2026, 09:54 AM UTC
Intel Shares Plummet Premarket After Q3 Revenue Miss and Weak Q4 Outlook
M impact | EQUITY | Oct 30, 2026, 09:54 AM UTC
NatWest shares extend fall, down 8.4%
M impact | EQUITY | Oct 30, 2026, 09:53 AM UTC
Airbus Q3 2026 Revenue Consensus Forecast
Consensus forecasts Airbus revenue for the third quarter of 2026.
M impact | EQUITY | Oct 30, 2026, 09:43 AM UTC
Strategy CFO Resigns as Company Reports Record Quarterly Profit
Strategy shares fell 6%. The supplied report does not identify the CFO or provide details on the quarterly profit.
M impact | EQUITY | Oct 30, 2026, 09:41 AM UTC
Prudential raises deemed stake in Solarvest to 5.646%
Prudential increased its deemed stake in Solarvest to 5.646%.
M impact | EQUITY | Oct 30, 2026, 09:41 AM UTC